Reverse stage shift at a tertiary care center: Escalating risk in men undergoing radical prostatectomy

Cancer

Volumn 117, Issue 21, 2011, Pages 4855-4860

  Silberstein, Jonathan L ^a   Vickers, Andrew J ^a   Power, Nicholas E ^a   Fine, Samson W ^a   Scardino, Peter T ^a   Eastham, James A ^a   Laudone, Vincent P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

active surveillance; minimally invasive surgery; prostate cancer; prostatectomy; prostatic neoplasm; risk; robotic

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER STAGING; CANCER SURGERY; FOLLOW UP; GLEASON SCORE; HUMAN; INTERVENTION STUDY; LAPAROSCOPIC SURGERY; MAJOR CLINICAL STUDY; MALE; MINIMALLY INVASIVE SURGERY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; ROBOTICS; SURGICAL APPROACH; SURGICAL TECHNIQUE; TERTIARY HEALTH CARE; TREATMENT INDICATION; TREND STUDY;

HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

EID: 80054806323     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26132     Document Type: Article

References (20)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. D'Amico AV, Desjardin A, Chung A, et al. Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. Cancer. 1998; 82: 1887-1896. (Pubitemid 28208644)
3. Barbash GI, Glied SA,. New technology and health care costs-the case of robot-assisted surgery. N Engl J Med. 2010; 363: 701-704.
4. Klotz L,. Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer. J Urol. 2004; 172 (5 pt 2): S48-S50; discussion S50-S51.
5. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
6. Mohler J, Bahnson RR, Boston B, et al. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. J Natl Compr Canc Netw. 2010; 8: 162-200.
7. Derweesh IH, Kupelian PA, Zippe C, et al. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol. 2004; 22: 300-306. (Pubitemid 38993307)
8. Brawley OW,. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer. 1997; 80: 1857-1863. (Pubitemid 27475949)
9. Ellis WJ, Lange PH,. Point: open radical prostatectomy should not be abandoned. J Natl Compr Canc Netw. 2007; 5: 685-688. (Pubitemid 47265561)
10. Lee EK, Baack J, Duchene DA,. Survey of practicing urologists: robotic versus open radical prostatectomy. Can J Urol. 2010; 17: 5094-5098.
11. Kuroiwa K, Uchino H, Yokomizo A, Naito S,. Impact of reporting rules of biopsy Gleason score for prostate cancer. J Clin Pathol. 2009; 62: 260-263.
12. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL,. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005; 29: 1228-1242. (Pubitemid 41232997)
13. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL,. Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists. Adv Anat Pathol. 2006; 13: 57-59. (Pubitemid 44357147)
14. Cooperberg MR, Broering JM, Carroll PR,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010; 28: 1117-1123.
15. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360: 1320-1328.
16. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR,. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007; 178 (3 pt 2): S14-S19. (Pubitemid 47224952)
17. Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD,. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol. 2008; 180: 1964-1967; discussion 1967-1968.
18. Adamy A, Yee DS, Matsushita K, et al. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol. 2011; 185: 477-482.
19. Heidenreich A, Bellmunt J, Bolla M, et al. EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease. Eur Urol. 2011; 59: 61-71.
20. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007; 177: 2106-2131. (Pubitemid 46726449)